GABA Analogues for Neuropathic Pain via Alpha2δ-1 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for treating pain and central nervous system disorders, such as gabapentin and pregabalin, have limitations including short half-life, mild side effects, and limited selectivity for specific α2δ subunits, which affect their efficacy and tolerability.
Innovation Solution
Development of novel γ-aminobutyric acid derivatives, specifically compounds of Formula 1, which bind with high affinity to the α2δ-1 subunit of voltage-gated calcium channels, offering improved therapeutic profiles for neuropathic pain and central nervous system disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If gabapentin or pregabalin are used to treat pain and CNS disorders, then they bind to α2δ subunits and provide therapeutic effects, but they have short half-life and require frequent dosing
Solution Approach 1:
The patent modifies the chemical structure of gabapentin by introducing cyclic constraints and substituent groups (Formula 1 compounds) to alter pharmacokinetic properties. This structural parameter change extends the half-life of the drug, allowing for less frequent dosing while maintaining therapeutic efficacy.
2Ease of operation
If gabapentin is designed as a lipophilic GABA analogue, then it can cross the blood-brain barrier via L-system transporter, but it does not interact with GABA receptors or metabolic enzymes
Solution Approach 1:
The patent utilizes the L-system amino acid transporter as an intermediary mechanism to deliver the modified GABA analogues across the blood-brain barrier. The compounds are designed to be recognized by this transporter system, enabling CNS penetration without requiring direct interaction with GABA receptors, thus maintaining the successful delivery mechanism while improving therapeutic profile.
3Object-affected harmful factors
If gabapentin and pregabalin are made hydrophilic and doubly-charged at neutral pH, then they have reduced toxic side effects, but they become insoluble in lipids and require specialized transporter systems
Solution Approach 1:
The patent maintains the hydrophilic, doubly-charged nature of the compounds at physiological pH to minimize toxic side effects, while introducing cyclic structural elements and specific substituents that enhance membrane permeability. This parameter optimization allows the drugs to retain their safety profile while improving their ability to cross biological membranes, potentially reducing dependence on specialized transporter systems.
Data Source
AI summary
A compound of Formula (1) wherein R1 represents hydrogen, halo, a C1-C4 alkyl group, a C1-C4 alkylhalide group, a C1-C4 alkoxy-C2-C4 alkyl group, a C2-C4 alkenyl group, a C2-C4 alkynyl group or a C3- C7 cyclo alkyl group; R2 represents Formula (1)' or Formula (1)'' a tautomer thereof; and R3 represents hydrogen, a C1-C4 alkyl group, a C1-C4 alkoxy-C2-C4 alkyl group or a C7 cyclo alkyl group; or a pharmaceutically acceptable salt or solvate thereof. Processes to prepare said compounds and novel intermediates are also claimed. Such compound finds utility in treating neuropathic pain and disorders of the central nervous system.